Suzhou Basecare Medical (HKG:2170) saw its shares surge by nearly 10% on Wednesday after the company announced that it has obtained approval for the renewal of the registration certificate for its PGT-A kit from China's National Medical Products Administration.
The PGT-A kit is used for accurately detecting DNA abnormalities in embryos, and the renewed registration certificate is valid until February 20, 2030.
The positive regulatory development for one of the company's key products was welcomed by investors, driving the stock price higher on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。